Acute Myelogenous Leukemia

Vion Pharmaceuticals Enters into an Agreement to Sell Convertible Senior Notes and Warrants

Published in Drug Week, March 9th, 2007

VION PHARMACEUTICALS, INC. (Nasdaq Capital Market: VION) announced an agreement to sell up to $60 million principal amount of its Convertible Senior Notes due 2012 and Warrants to purchase up to 7,800,000 shares of Vion common stock in a private placement.

The notes will bear interest at a rate of 7.75% per annum and be convertible into shares of Vion's common stock at an initial conversion rate of 520.833 shares of common stock per $1,000 principal amount of notes, subject to adjustment (equivalent to an initial conversion price of $1.92 per share, representing a conversion premium of 20% to the last reported sale price of $1.60 per share on February 13, 2007). Subject...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2007-03-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry